1. Which of the following correctly describes why immediate-release nifedipine is contraindicated for chronic hypertension management while long-acting formulations (GITS, XL) are acceptable?
A) Immediate-release nifedipine irreversibly blocks L-type calcium channels, causing permanent vasodilation that cannot be titrated
B) Immediate-release nifedipine is absorbed sublingually and achieves toxic CNS concentrations not reached by oral long-acting formulations
C) Immediate-release nifedipine produces an abrupt plasma concentration peak causing intense reflex sympathetic activation — tachycardia, catecholamine surge, and increased myocardial oxygen demand — associated with increased cardiovascular events; long-acting formulations provide gradual controlled release that avoids this reflex
D) Immediate-release nifedipine blocks both L-type and T-type calcium channels; long-acting formulations are selective for L-type channels only
E) Immediate-release nifedipine causes rebound hypertension on discontinuation through receptor upregulation; long-acting formulations taper plasma levels gradually
ANSWER: C
Rationale:
The safety distinction between immediate-release and long-acting nifedipine is entirely pharmacokinetic — the drug is identical in both formulations. Immediate-release nifedipine produces a steep, rapid plasma concentration peak that causes abrupt intense arteriolar vasodilation. The sudden fall in blood pressure triggers a powerful reflex sympathetic response — tachycardia, increased myocardial oxygen demand, catecholamine release — associated with increased adverse cardiovascular events including myocardial infarction. Long-acting formulations (GITS, XL, CC) deliver nifedipine continuously over 24 hours without the concentration peak, avoiding the reflex.
Option A: Option A is incorrect because nifedipine's L-type channel blockade is competitive and reversible in all formulations.
Option B: Option B is incorrect because nifedipine is not absorbed sublingually and CNS toxicity is not the mechanism of cardiovascular harm.
Option D: Option D is incorrect because both formulations are dihydropyridines acting on L-type channels only.
Option E: Option E is incorrect because rebound hypertension on discontinuation is characteristic of centrally acting sympatholytics such as clonidine, not calcium channel blockers.
2. Verapamil is a potent CYP3A4 inhibitor. A patient with hypertension and atrial fibrillation is started on verapamil for rate control and is also taking atorvastatin 40 mg daily. Which of the following correctly describes the drug interaction and the most appropriate clinical response?
A) Verapamil inhibits CYP3A4, reducing first-pass and systemic metabolism of atorvastatin and raising its plasma concentrations, increasing the risk of statin-induced myopathy; the appropriate response is to switch to a statin not dependent on CYP3A4 — such as rosuvastatin or pravastatin — or to reduce the atorvastatin dose with monitoring
B) Verapamil induces CYP3A4 and reduces atorvastatin levels, requiring a dose increase of atorvastatin to maintain lipid-lowering efficacy
C) Verapamil competes with atorvastatin for plasma protein binding, transiently raising free atorvastatin and causing reversible myopathy that resolves without dose adjustment
D) Verapamil and atorvastatin share OATP1B1 hepatic uptake transporters, causing additive hepatotoxicity requiring liver function monitoring every two weeks
E) Verapamil causes hypokalemia that sensitizes skeletal muscle to atorvastatin myotoxicity; potassium supplementation prevents the interaction
ANSWER: A
Rationale:
Verapamil is a clinically significant CYP3A4 inhibitor. Atorvastatin is primarily metabolized by CYP3A4; when verapamil inhibits this enzyme, first-pass and systemic metabolism of atorvastatin is reduced, raising plasma concentrations and increasing the risk of statin-related myopathy — ranging from myalgia to rhabdomyolysis in severe cases. The clinical response is to switch to a statin that does not depend on CYP3A4 — rosuvastatin (minimally CYP-metabolized) or pravastatin (not CYP3A4-dependent) are preferred alternatives — or to reduce the atorvastatin dose with close monitoring.
Option B: Option B is incorrect because verapamil inhibits CYP3A4, it does not induce it; CYP3A4 induction reducing statin levels is caused by rifampin, carbamazepine, and St. John's wort.
Option C: Option C is incorrect because protein displacement is not the mechanism of the verapamil-atorvastatin interaction and is rarely clinically significant for most drugs.
Option D: Option D is incorrect because while OATP1B1 interactions affect certain statins with some inhibitors, the primary verapamil-atorvastatin interaction is CYP3A4 inhibition; additive hepatotoxicity is not the clinical concern.
Option E: Option E is incorrect because verapamil does not cause hypokalemia, and electrolyte imbalance is not the mechanism of statin myopathy in this context.
3. Liddle syndrome is a rare genetic disorder of constitutively active epithelial sodium channels (ENaC) in the collecting duct, causing severe hypertension with suppressed renin and very low aldosterone. Which of the following correctly identifies the appropriate drug and explains why the other potassium-sparing diuretic is ineffective?
A) Spironolactone is the drug of choice because it blocks the mineralocorticoid receptor, which drives ENaC overactivity regardless of aldosterone levels in Liddle syndrome
B) Either amiloride or spironolactone is equally effective because both ultimately reduce ENaC-mediated sodium reabsorption regardless of mechanism
C) Amiloride is ineffective in Liddle syndrome because it requires aldosterone to open ENaC before it can occlude the channel pore
D) Amiloride is the drug of choice because it directly blocks the ENaC pore independently of aldosterone; spironolactone is ineffective because it antagonizes the mineralocorticoid receptor — and in Liddle syndrome aldosterone is low and the constitutively active ENaC mutation is not driven by aldosterone receptor signaling
E) Spironolactone is preferred because its active metabolite canrenone has direct ENaC-blocking properties that are enhanced in constitutive channel overactivity
ANSWER: D
Rationale:
Liddle syndrome is caused by gain-of-function mutations in the beta or gamma subunits of ENaC, keeping the channel constitutively open regardless of aldosterone. Aldosterone is actually suppressed due to volume expansion inhibiting the RAAS. Amiloride directly occludes the ENaC pore at the luminal surface of collecting duct principal cells — an action entirely independent of aldosterone — and is therefore effective. Spironolactone antagonizes the mineralocorticoid receptor, blocking aldosterone-driven transcription of ENaC subunits. In Liddle syndrome, ENaC overactivity is not driven by aldosterone receptor signaling — the channel is constitutively open by mutation. Blocking a receptor that is not driving the pathology accomplishes nothing. Spironolactone is clinically ineffective in Liddle syndrome.
Option A: Option A is incorrect because the mineralocorticoid receptor is not overactive in Liddle syndrome; the pathology is in the channel itself.
Option B: Option B is incorrect because only amiloride is effective; the mechanisms are not clinically interchangeable here.
Option C: Option C is incorrect because amiloride does not require aldosterone — its ENaC blockade is aldosterone-independent.
Option E: Option E is incorrect because canrenone does not have clinically relevant direct ENaC-blocking properties.
4. The ALLHAT trial enrolled over 33,000 high-risk hypertensive patients and compared chlorthalidone, amlodipine, and lisinopril as first-line agents. Which of the following correctly summarizes the key finding regarding racial differences in outcomes?
A) Lisinopril was superior to chlorthalidone for stroke prevention in Black patients, establishing ACE inhibitors as the preferred first-line agent across all demographic groups
B) Chlorthalidone was superior to lisinopril for stroke prevention and heart failure prevention in Black patients, consistent with the lower efficacy of RAAS inhibitors as monotherapy in this population due to their lower-renin physiology; amlodipine was equivalent to chlorthalidone for the primary cardiovascular endpoint across racial groups
C) Amlodipine was inferior to chlorthalidone for all endpoints in Black patients, establishing that CCBs should be avoided as monotherapy in this demographic
D) All three agents produced identical outcomes in Black patients, confirming that drug class is irrelevant when blood pressure targets are achieved regardless of renin status
E) The racial outcome differences in ALLHAT were entirely attributable to differences in achieved blood pressure between the three arms, not to pharmacological class differences
ANSWER: B
Rationale:
ALLHAT enrolled approximately 35% Black patients, making it one of the most informative trials on racial pharmacological differences in hypertension. A key finding was that lisinopril was inferior to chlorthalidone for stroke prevention and heart failure prevention in Black patients — consistent with the well-established observation that RAAS inhibitors are less effective as monotherapy in Black patients, who typically have lower-renin, volume-expanded hypertension that is less angiotensin II-dependent. Amlodipine, acting through a renin-independent vascular mechanism, was equivalent to chlorthalidone for the primary composite cardiovascular endpoint across racial groups. These findings reinforced guideline recommendations for CCBs and thiazide-type diuretics as preferred first-line agents in Black patients without compelling indications for RAAS inhibition.
Option A: Option A is incorrect — lisinopril was inferior, not superior, to chlorthalidone for stroke in Black patients.
Option C: Option C is incorrect — amlodipine was equivalent to chlorthalidone for the primary endpoint.
Option D: Option D is incorrect — ALLHAT demonstrated meaningful outcome differences between agents, particularly in Black patients.
Option E: Option E is incorrect — the racial disparity persisted even after accounting for achieved blood pressure, suggesting pharmacological class differences beyond BP lowering.
5. Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) with a distinct pharmacological profile from spironolactone and eplerenone. Which of the following correctly identifies a key clinical advantage of finerenone over spironolactone specifically in patients with diabetic CKD on background RAAS inhibition?
A) Finerenone has a longer half-life than spironolactone, allowing once-weekly dosing that improves adherence in complex multidrug regimens
B) Finerenone blocks aldosterone synthesis in the adrenal gland rather than antagonizing the receptor, providing more complete mineralocorticoid suppression
C) Finerenone does not cross the blood-brain barrier, eliminating the CNS adverse effects of spironolactone
D) Finerenone is more potent at the mineralocorticoid receptor than spironolactone, requiring lower doses that proportionally reduce all class-related adverse effects
E) Finerenone causes less hyperkalemia than spironolactone at cardiorenal-protective doses and has no sex hormone-related adverse effects because it does not bind androgen or progesterone receptors — making it better tolerated for long-term use in diabetic CKD where ongoing RAAS inhibition already raises hyperkalemia risk
ANSWER: E
Rationale:
Finerenone's two key advantages over spironolactone in the context of diabetic CKD are well established. First, finerenone causes less hyperkalemia at the doses used for cardiorenal protection — partly due to its balanced tissue distribution between the kidney and heart, producing antifibrotic and anti-inflammatory MR blockade with proportionally less renal MR blockade that drives potassium retention. In patients already at hyperkalemia risk from RAAS inhibitors plus CKD, this is clinically important. Second, finerenone is highly selective for the mineralocorticoid receptor and does not bind androgen or progesterone receptors, eliminating the sex hormone-related adverse effects of spironolactone — gynecomastia, breast tenderness, menstrual irregularities, and erectile dysfunction — that cause significant rates of spironolactone discontinuation in clinical practice.
Option A: Option A is incorrect because finerenone is dosed once daily, not once weekly.
Option B: Option B is incorrect because finerenone antagonizes the mineralocorticoid receptor — it does not block aldosterone synthesis; that would be a different mechanism entirely.
Option C: Option C is incorrect because CNS penetration is not a clinically recognized mechanism of spironolactone adverse effects; the sex hormone adverse effects are peripheral.
Option D: Option D is incorrect because while finerenone has favorable pharmacological properties, the statement that lower doses proportionally reduce all adverse effects does not accurately describe the basis of finerenone's clinical advantage.
6. A 68-year-old man with HFrEF (ejection fraction 30%), permanent atrial fibrillation, and hypertension is on carvedilol 25 mg twice daily and lisinopril 10 mg daily. BP is 152/88 mmHg. His physician wants to add a CCB for additional blood pressure control. Which is most appropriate?
A) Verapamil 120 mg twice daily — non-DHP CCBs provide rate control benefit in AF and the negative inotropy is offset by the existing beta-blocker
B) Diltiazem 120 mg twice daily — diltiazem's intermediate cardiac selectivity makes it safer than verapamil in HFrEF
C) Amlodipine 5 mg daily — the only CCB subclass that can be used cautiously in HFrEF; V-HeFT III established amlodipine as hemodynamically neutral in HFrEF; it provides antihypertensive benefit without worsening cardiac function
D) Nicardipine IV titration — intravenous DHP CCBs are preferred in HFrEF because they can be precisely titrated without cardiac effects
E) Felodipine 5 mg daily — felodipine is the only DHP CCB proven to improve ejection fraction in HFrEF and is therefore preferred over amlodipine
ANSWER: C
Rationale:
In HFrEF, CCB selection is critically constrained by negative inotropic risk. Both verapamil and diltiazem — non-dihydropyridine CCBs — are contraindicated in HFrEF because their cardiac L-type calcium channel blockade worsens contractility in a heart with already impaired systolic function, increasing mortality risk. Amlodipine, a dihydropyridine with high vascular selectivity and minimal direct cardiac contractility effects, was specifically studied in HFrEF in the V-HeFT III trial and found hemodynamically neutral — it neither worsened ejection fraction nor increased mortality. It can therefore be used cautiously for blood pressure control when needed. It will not contribute to AF rate control (DHP CCBs do not slow AV conduction), but carvedilol addresses that.
Option A: Option A is incorrect because adding verapamil to carvedilol risks severe bradycardia and complete heart block — a contraindicated combination — and verapamil's negative inotropy is additive with, not offset by, beta-blockade.
Option B: Option B is incorrect for the same fundamental reasons — diltiazem is also contraindicated in HFrEF.
Option D: Option D is incorrect because nicardipine IV is used in hypertensive emergencies, not chronic HFrEF management.
Option E: Option E is incorrect because felodipine does not improve ejection fraction in HFrEF; like amlodipine it is hemodynamically neutral, and amlodipine has the stronger evidence base in this setting.
7. A 55-year-old man with hypertension and a history of recurrent gout (serum uric acid 8.8 mg/dL; on allopurinol) requires antihypertensive therapy including a RAAS inhibitor. Which specific RAAS inhibitor has a uricosuric property that makes it particularly appropriate when a thiazide must also be used in this patient?
A) Losartan — uniquely among ARBs and among all antihypertensive drug classes, it inhibits the URAT1 transporter (proximal tubular urate reabsorption transporter) in the proximal tubule, increasing urinary uric acid excretion and partially offsetting thiazide-associated hyperuricemia; this property is not shared by other ARBs or ACE inhibitors
B) Lisinopril — ACE inhibitors reduce angiotensin II-driven proximal tubular urate reabsorption as a class effect, making all ACE inhibitors clinically uricosuric
C) Ramipril — its active metabolite ramiprilat has the strongest uricosuric effect among RAAS inhibitors through direct xanthine oxidase inhibition
D) Valsartan — it has the greatest URAT1 inhibition among all ARBs, exceeding losartan's uricosuric potency at standard therapeutic doses
E) Candesartan — it inhibits a collecting duct uric acid secretion transporter, providing a uricosuric mechanism distinct from and additive with proximal tubular transport inhibition
ANSWER: A
Rationale:
Losartan is unique among antihypertensive agents in possessing a clinically meaningful uricosuric property. Losartan and its active metabolite EXP3174 inhibit URAT1 in the proximal tubule, reducing urate reabsorption from the tubular lumen and increasing urinary uric acid excretion. This property lowers serum uric acid and is not shared by other ARBs or ACE inhibitors as a class. In a patient with hypertension, gout, and a requirement for both a RAAS inhibitor and a thiazide diuretic — which raises uric acid — using losartan as the RAAS inhibitor provides partial pharmacological protection against thiazide-associated hyperuricemia while also providing antihypertensive efficacy and cardiovascular organ protection.
Option B: Option B is incorrect because ACE inhibitors do not have clinically established uricosuric activity; angiotensin II reduction does not meaningfully lower serum uric acid in clinical practice.
Option C: Option C is incorrect because ramipril does not inhibit xanthine oxidase; that mechanism belongs to allopurinol and febuxostat.
Option D: Option D is incorrect because valsartan does not have significant URAT1 inhibition; the uricosuric property is specific to losartan.
Option E: Option E is incorrect because candesartan does not have a clinically established collecting duct uricosuric mechanism.
8. The ACCOMPLISH trial demonstrated superiority of benazepril plus amlodipine over benazepril plus HCTZ for cardiovascular event reduction despite similar blood pressure reductions in both arms. Which of the following provides the most pharmacologically complete explanation for this finding?
A) Amlodipine caused more peripheral edema than HCTZ, which paradoxically reduced cardiovascular risk by lowering blood viscosity
B) HCTZ caused sufficient hypokalemia and new-onset diabetes in the diuretic arm to fully account for the cardiovascular outcome difference between the two regimens
C) Benazepril is intrinsically more effective when combined with amlodipine because amlodipine activates the RAAS through vasodilation, enhancing ACE inhibitor efficacy through synergistic mechanism
D) The CCB combination likely provided superior 24-hour blood pressure coverage from amlodipine's long half-life, pleiotropic antiatherosclerotic effects demonstrated in CAMELOT, more favorable central aortic pressure reduction, and RAAS inhibitor mitigation of CCB-associated peripheral edema — collectively contributing to cardiovascular benefit beyond measured brachial blood pressure reduction
E) Amlodipine has established antithrombotic properties that reduce platelet aggregation independently of blood pressure lowering, accounting for the majority of the cardiovascular benefit difference
ANSWER: D
Rationale:
The ACCOMPLISH finding — superior cardiovascular outcomes with the CCB-based combination despite similar measured blood pressure — prompted significant discussion about the mechanisms of benefit. Several pharmacological explanations are likely collectively operative. Amlodipine's antiatherosclerotic effects were demonstrated in the CAMELOT trial, which showed reduced cardiovascular events and slowed atherosclerosis progression in stable CAD patients. The CCB plus RAAS inhibitor combination may reduce central aortic pressure more favorably than measured brachial blood pressure suggests, since central pressure is more predictive of cardiovascular events. Amlodipine's 35–50 hour half-life provides more consistent 24-hour coverage than HCTZ's 10–12 hour half-life, potentially reducing morning blood pressure surge. The RAAS inhibitor mitigates CCB-associated peripheral edema through venodilation, improving patient tolerance and possibly vascular compliance. No single mechanism fully explains the ACCOMPLISH result; the combination of these factors is the most complete explanation.
Option A: Option A is incorrect and describes a pharmacologically implausible mechanism.
Option B: Option B is incorrect because metabolic adverse effects of HCTZ did not fully account for the outcome difference in ACCOMPLISH analyses.
Option C: Option C is incorrect because amlodipine does not activate the RAAS; it is the diuretic through volume contraction that activates the RAAS and enhances ACE inhibitor efficacy.
Option E: Option E is incorrect because amlodipine does not have established clinically relevant antithrombotic properties.
9. A 62-year-old woman with primary aldosteronism from bilateral adrenal hyperplasia is started on spironolactone with excellent blood pressure control. Six weeks later she reports significant breast tenderness and gynecomastia-equivalent tissue swelling. Her potassium is 4.9 mEq/L and creatinine is stable. She requests a pharmacological substitution. Which is most appropriate?
A) Switch to amiloride — it blocks ENaC directly and will maintain potassium-sparing and antihypertensive benefit without sex hormone receptor binding
B) Switch to eplerenone — a selective steroidal MRA that does not bind androgen or progesterone receptors, eliminating sex hormone-related adverse effects; note that eplerenone is approximately 40–50x less potent than spironolactone at the mineralocorticoid receptor and requires higher doses (up to 50 mg twice daily) for equivalent mineralocorticoid blockade
C) Switch to furosemide — loop diuretics provide sufficient mineralocorticoid pathway blockade to control primary aldosteronism without sex hormone side effects
D) Switch to chlorthalidone — thiazide-type diuretics act downstream of aldosterone and will maintain blood pressure control without hormonal adverse effects
E) Switch to finerenone — a non-steroidal MRA without sex hormone adverse effects; however, its primary evidence base is in diabetic CKD rather than primary aldosteronism, making eplerenone the more guideline-supported first substitution in this specific setting
ANSWER: B
Rationale:
When spironolactone causes intolerable sex hormone-related adverse effects — gynecomastia, breast tenderness, menstrual irregularities, or erectile dysfunction — in a patient with primary aldosteronism requiring ongoing mineralocorticoid receptor antagonism, eplerenone is the guideline-supported first substitution. Eplerenone is a selective MRA that binds the mineralocorticoid receptor without significant affinity for androgen or progesterone receptors, eliminating the sex hormone-mediated adverse effects entirely. It is approximately 40–50x less potent than spironolactone at the MR on a per-milligram basis, so doses of up to 50 mg twice daily may be required for equivalent blood pressure and potassium control — a practical consideration when switching. Option E contains accurate information but correctly identifies that eplerenone is the more guideline-supported first substitution in primary aldosteronism over finerenone at this time.
Option A: Option A is incorrect because amiloride blocks ENaC directly and independently of aldosterone, providing potassium-sparing benefit but without the mineralocorticoid receptor blockade needed for the full blood pressure correction and aldosterone-antagonism that primary aldosteronism requires; in bilateral adrenal hyperplasia, MR blockade is the pharmacological goal.
Option C: Option C is incorrect because furosemide does not block the mineralocorticoid receptor and would worsen hypokalemia.
Option D: Option D is incorrect because thiazides act at the distal convoluted tubule and do not block the MR; they would worsen hypokalemia.
10. Loop diuretics become the preferred diuretic class over thiazides in specific clinical situations. Which of the following most accurately identifies when this substitution is appropriate in hypertension management?
A) When the patient is older than 65, because loop diuretics cause less orthostatic hypotension and hyponatremia than thiazides in the elderly
B) When the patient has heart failure with preserved ejection fraction, because loop diuretics specifically reduce diastolic stiffness through their calciuric properties
C) When the patient has diabetes mellitus, because loop diuretics have a more favorable glucose and uric acid metabolic profile than thiazides at equivalent diuretic doses
D) When resistant hypertension requires combination diuretic therapy, because loop diuretics are always combined with thiazides before potassium-sparing agents are considered as a step in the resistant HTN algorithm
E) When eGFR falls below approximately 30 mL/min/1.73m2, where thiazide efficacy is substantially reduced because decreased tubular secretion limits NCC transporter delivery and reduced nephron mass limits the natriuretic response; loop diuretics retain efficacy at low eGFR because NKCC2 in the thick ascending limb remains functional even with advanced CKD
ANSWER: E
Rationale:
The primary clinical indication for replacing thiazide-type diuretics with loop diuretics in hypertension is advanced CKD — specifically when eGFR falls below approximately 30 mL/min/1.73m2. Thiazide efficacy depends on tubular secretion of the drug into the proximal tubular lumen for delivery to the DCT, where it inhibits NCC. In advanced CKD, reduced tubular secretion decreases drug delivery to NCC, and reduced nephron mass means fewer functional NCC transporters are available. The resulting natriuretic and antihypertensive response to thiazides falls substantially. Loop diuretics inhibit NKCC2 in the thick ascending limb, which remains accessible in advanced CKD; their efficacy is maintained at low eGFR, though higher doses may be required. Among thiazide-like agents, indapamide retains better efficacy at lower eGFR than HCTZ or chlorthalidone.
Option A: Option A is incorrect because loop diuretics are not preferred over thiazides in the elderly based on age alone — thiazides are highly effective in elderly isolated systolic hypertension (SHEP, HYVET).
Option B: Option B is incorrect because loop diuretics do not specifically reduce diastolic stiffness through calciuria.
Option C: Option C is incorrect because loop diuretics are not metabolically favorable compared to thiazides — they have similar or greater potassium wasting and hyperuricemia risk.
Option D: Option D is incorrect because the standard resistant hypertension algorithm adds spironolactone as the fourth agent (PATHWAY-2); a mandatory loop-thiazide combination step is not part of the established algorithm.
11. Torsemide and furosemide are both loop diuretics but torsemide has pharmacokinetic advantages in oral outpatient use. Which of the following correctly identifies these advantages?
A) Torsemide inhibits a different loop transporter (NKCC1) than furosemide (NKCC2), producing greater natriuresis with less potassium wasting
B) Torsemide has proven superiority over furosemide for all-cause mortality in heart failure as demonstrated in the TRANSFORM-HF trial, establishing it as standard of care in all HFrEF patients
C) Torsemide has approximately 80% oral bioavailability with low inter-patient variability and a half-life of approximately 3.5 hours with predominantly hepatic metabolism, compared to furosemide's highly variable oral bioavailability averaging approximately 50% and short half-life of approximately 2 hours; this makes torsemide's diuretic response more consistent and predictable in outpatient use
D) Torsemide is preferred in CKD because its renal elimination avoids the reduced tubular secretion that limits furosemide delivery to NKCC2 in advanced renal failure
E) Torsemide lacks ototoxicity risk compared to furosemide because its higher protein binding prevents it from reaching the endolymph of the inner ear
ANSWER: C
Rationale:
The pharmacokinetic advantages of torsemide over furosemide in oral outpatient use are well established. Furosemide has notoriously variable oral bioavailability — averaging approximately 50% but ranging from 10% to nearly 100% between and within individual patients — and a short half-life of approximately 2 hours requiring twice-daily dosing. This variability makes outpatient diuretic titration with furosemide unpredictable. Torsemide has approximately 80% oral bioavailability with considerably less inter-patient variability, and its half-life of approximately 3.5 hours with predominantly hepatic metabolism (~80%) supports once-daily dosing with a more consistent and predictable response.
Option A: Option A is incorrect because both torsemide and furosemide inhibit NKCC2 in the thick ascending limb; neither inhibits NKCC1.
Option B: Option B is incorrect because TRANSFORM-HF did not demonstrate torsemide superiority over furosemide for all-cause mortality — the primary endpoint was not met; torsemide's advantages remain pharmacokinetic rather than proven mortality-reducing in large trials.
Option D: Option D is incorrect because torsemide's advantage in CKD relates to its hepatic metabolism reducing dependence on renal elimination, not avoidance of tubular secretion issues for NKCC2 delivery, which affects both agents similarly.
Option E: Option E is incorrect because both loop diuretics reach the endolymph and carry ototoxicity risk at high doses or with concurrent aminoglycosides; ethacrynic acid carries the highest ototoxicity risk among loop diuretics.
12. A 65-year-old man with hypertension and three recurrent calcium oxalate kidney stones has a 24-hour urine calcium of 380 mg/day (normal less than 300 mg/day) and eGFR of 72 mL/min/1.73m2. Serum calcium is normal. Which antihypertensive agent is most appropriate given his stone history?
A) Chlorthalidone 12.5 mg daily — thiazide-type diuretics reduce urinary calcium excretion (hypocalciuria) by enhancing passive calcium reabsorption in the distal convoluted tubule via a mechanism linked to NCC inhibition; this directly reduces the urinary calcium driving stone formation; chlorthalidone's long half-life provides sustained hypocalciuric effect from once-daily dosing
B) Furosemide 20 mg daily — loop diuretics increase calcium excretion by up to 50%, rapidly normalizing his hypercalciuria
C) Lisinopril 10 mg daily — ACE inhibitors reduce glomerular filtration pressure, lowering the filtered calcium load and thereby reducing urinary calcium
D) Amlodipine 5 mg daily — DHP CCBs block calcium entry into tubular epithelial cells, reducing calcium available for urinary excretion
E) Spironolactone 25 mg daily — mineralocorticoid receptor antagonism reduces intestinal calcium absorption by blocking aldosterone-driven calcium transport
ANSWER: A
Rationale:
Thiazide and thiazide-like diuretics are the antihypertensive agents of choice when a hypertensive patient has hypercalciuria and recurrent calcium nephrolithiasis. NCC inhibition in the DCT lowers intracellular sodium in tubular cells, enhancing the electrochemical gradient driving passive calcium reabsorption via apical TRPV5 channels. Net calcium reabsorption in the DCT increases and urinary calcium excretion falls — directly reducing the urinary calcium supersaturation that drives calcium oxalate stone nucleation. Chlorthalidone is preferred over HCTZ for this purpose given its longer half-life and more sustained hypocalciuric effect from once-daily dosing.
Option B: Option B is incorrect because loop diuretics do the opposite — they increase urinary calcium excretion (calciuria) by abolishing the lumen-positive voltage in the thick ascending limb that drives paracellular calcium reabsorption; loop diuretics would worsen this patient's nephrolithiasis.
Option C: Option C is incorrect because ACE inhibitors do not have a specific tubular calcium-handling effect that reduces urinary calcium through this mechanism.
Option D: Option D is incorrect because DHP CCBs act on vascular smooth muscle calcium channels, not on renal tubular calcium transport channels; their mechanism does not reduce urinary calcium.
Option E: Option E is incorrect because spironolactone does not have a clinically established mechanism for reducing intestinal calcium absorption through aldosterone receptor blockade.
13. A 74-year-old woman with isolated systolic hypertension is started on chlorthalidone 25 mg daily. She weighs 49 kg, is small-framed, and drinks approximately 2.5 liters of water daily. Eight weeks later her serum sodium is 118 mEq/L and she is confused. Which factor most amplifies her susceptibility to thiazide-associated severe hyponatremia compared to a larger patient on the same dose?
A) Her advanced age reduces aldosterone secretion, impairing the renal sodium retention needed to compensate for thiazide-driven losses
B) Her isolated systolic hypertension indicates arterial stiffness, which impairs baroreceptor-mediated ADH suppression and causes persistent ADH elevation
C) Her high fluid intake directly activates hypothalamic osmoreceptors, triggering ADH release that compounds the volume-depletion ADH stimulus from chlorthalidone
D) Her small body size means she has less total body water; the same absolute sodium loss and free water retention from ADH stimulation produce a proportionally larger fall in serum sodium compared to a larger patient with greater total body water buffering capacity
E) Chlorthalidone's longer half-life than HCTZ means it accumulates to toxic plasma levels in small elderly patients, causing disproportionate tubular sodium wasting
ANSWER: D
Rationale:
The primary vulnerability amplifying this patient's hyponatremia risk is her small body size and correspondingly small total body water volume. Thiazide-associated hyponatremia involves sodium loss from NCC inhibition combined with ADH-driven free water retention — volume contraction stimulates ADH, and thiazides impair the kidney's ability to excrete free water by preventing dilute urine generation. In a larger patient with greater total body water, the same absolute sodium deficit and free water retention produce a smaller proportional change in serum sodium concentration — the same numerator divided by a larger denominator. In a patient with 49 kg small body habitus, the same numerator divided by a smaller total body water volume produces a steeper fall in serum sodium. Her high fluid intake adds exogenous free water she cannot excrete due to thiazide-impaired urinary dilution, further amplifying the effect.
Option A: Option A is incorrect because reduced aldosterone with age is not the primary mechanism; the pathology is sodium loss combined with impaired free water excretion and ADH-driven retention.
Option B: Option B is incorrect because ISH and arterial stiffness do not cause persistent ADH elevation through an established baroreceptor impairment mechanism.
Option C: Option C is incorrect because high fluid intake in the setting of impaired free water excretion compounds hyponatremia but is not the primary amplifying factor — her small body size is; high intake in a person with normal free water excretion would be rapidly excreted.
Option E: Option E is incorrect because chlorthalidone does not accumulate to toxic plasma levels based on body size; its pharmacodynamic advantage over HCTZ is its longer half-life providing better coverage, not drug toxicity.
14. A 58-year-old man with hypertension on amlodipine 10 mg daily has well-controlled blood pressure but develops significant bilateral ankle edema. BNP is normal. His physician considers adding a RAAS inhibitor to address the edema mechanism. Which of the following best explains how a RAAS inhibitor would reduce CCB-associated edema?
A) RAAS inhibitors promote natriuresis through aldosterone suppression, reducing the sodium retention that causes CCB-associated edema
B) RAAS inhibitors cause efferent arteriolar dilation and venodilation, reducing capillary hydrostatic pressure at the downstream end of the capillary bed and directly counteracting the increased pressure caused by CCB-driven arteriolar dilation at the upstream end
C) RAAS inhibitors block angiotensin II-mediated vasoconstriction in lymphatic vessels, improving lymphatic drainage of edematous tissues
D) RAAS inhibitors reduce cardiac output through negative chronotropy, lowering the systemic capillary perfusion pressure that drives fluid into dependent tissues
E) RAAS inhibitors inhibit aldosterone-driven ENaC expression in vascular endothelium, reducing endothelial permeability and limiting capillary fluid leak into dependent tissues
ANSWER: B
Rationale:
CCB-associated peripheral edema arises from preferential arteriolar dilation without matched venodilation — arteriolar resistance falls, increasing capillary hydrostatic pressure in dependent tissues, while venous tone remains relatively unchanged and fluid accumulates in the interstitium. RAAS inhibitors counteract this specifically: angiotensin II constricts efferent arterioles and promotes venous tone; when RAAS inhibitors reduce angiotensin II, they cause efferent arteriolar dilation and venodilation. Efferent arteriolar dilation reduces downstream capillary hydrostatic pressure; venodilation increases venous capacitance and reduces the pressure gradient driving fluid out of capillaries. Together these effects reduce the capillary hydrostatic pressure imbalance that CCB arteriolar dilation created, directly addressing the mechanism. This is one reason the CCB plus RAAS inhibitor combination outperformed the CCB plus HCTZ combination in ACCOMPLISH — the RAAS inhibitor both provides antihypertensive synergy and mitigates CCB edema.
Option A: Option A is incorrect because CCB edema is not sodium-mediated volume overload; natriuresis from aldosterone suppression does not target the capillary hydrostatic pressure mechanism.
Option C: Option C is incorrect because RAAS inhibitors do not have an established mechanism of improving lymphatic drainage through angiotensin II blockade in lymphatics.
Option D: Option D is incorrect because RAAS inhibitors do not have negative chronotropic effects; reducing heart rate is a beta-blocker and non-DHP CCB mechanism.
Option E: Option E is incorrect because ENaC expression in vascular endothelium is not a clinically established mechanism by which RAAS inhibitors reduce capillary permeability.
15. A 52-year-old man with hypertension on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily has BP of 164/98 mmHg despite confirmed medication adherence and exclusion of secondary causes. His plasma renin activity (PRA — a measure of renin system activation) is low. His potassium is 3.9 mEq/L and eGFR is 64 mL/min/1.73m2. PATHWAY-2 established the preferred fourth-line agent in this situation. Which agent is most appropriate, and how does his low PRA inform the choice?
A) Bisoprolol 5 mg daily — low PRA indicates high sympathetic tone requiring adrenergic blockade; PATHWAY-2 showed bisoprolol was the most effective fourth-line agent overall
B) Doxazosin 4 mg daily — alpha-1 blockade is preferred in low-renin resistant hypertension because alpha-adrenoceptors mediate the volume-independent component of vascular resistance
C) Hydralazine 25 mg three times daily — direct vasodilators are the preferred fourth-line agent in resistant hypertension with preserved renal function
D) Amiloride 5 mg daily — ENaC blockade provides potassium-sparing benefit while addressing the volume retention component of resistant hypertension
E) Spironolactone 25 mg daily — PATHWAY-2 established spironolactone as the most effective fourth-line agent, and his low PRA specifically predicts a robust response by indicating volume-dependent, aldosterone-mediated hypertension where mineralocorticoid receptor antagonism directly targets the underlying physiology
ANSWER: E
Rationale:
PATHWAY-2 was a randomized crossover trial in patients with true resistant hypertension on three optimized agents including a diuretic. Spironolactone produced approximately 8.7 mmHg greater systolic blood pressure reduction than placebo and was significantly superior to bisoprolol and doxazosin. Crucially, the benefit was greatest in patients with low plasma renin activity — exactly this patient's profile. Low PRA in the context of resistant hypertension indicates that the renin system is already suppressed, most likely by relative mineralocorticoid excess and volume expansion that escapes diagnostic thresholds for primary aldosteronism. Adding a mineralocorticoid receptor antagonist directly targets this volume-dependent aldosterone-mediated physiology. His current potassium of 3.9 mEq/L on lisinopril plus chlorthalidone is actually at the lower end of normal — spironolactone will tend to raise potassium, which may be beneficial here, though monitoring within 4 weeks of initiation is mandatory given concurrent RAAS inhibition and CKD stage 3a.
Option A: Option A is incorrect because low PRA does not indicate high sympathetic tone — it indicates suppressed renin from volume expansion; bisoprolol was inferior to spironolactone in PATHWAY-2.
Option B: Option B is incorrect because doxazosin was also inferior to spironolactone in PATHWAY-2, and low PRA does not specifically predict alpha-blocker response.
Option C: Option C is incorrect because hydralazine is not a guideline-recommended fourth-line agent in resistant hypertension in this context.
Option D: Option D is incorrect because amiloride, while potassium-sparing, does not have the mineralocorticoid receptor antagonism that makes spironolactone specifically effective in low-renin resistant hypertension, and lacks PATHWAY-2 evidence.
16. A 66-year-old Black man with hypertension (BP 158/96 mmHg), no proteinuria, no diabetes, no heart failure, and eGFR 71 mL/min/1.73m2 is being started on antihypertensive monotherapy. Applying the pharmacological principles from this module, which of the following is most strongly supported by evidence and mechanistic rationale for initial therapy in this patient?
A) Lisinopril 10 mg daily — ACE inhibitors are the preferred first-line agent in all patients regardless of race because RAAS blockade addresses the most common pathophysiological mechanism of essential hypertension
B) Metoprolol succinate 50 mg daily — beta-blockers are highly effective in low-renin hypertension by reducing cardiac output and thereby reducing the volume-dependent component of elevated blood pressure
C) Amlodipine 5 mg daily — dihydropyridine CCBs act through a renin-independent vascular mechanism and are highly effective across all demographic groups; ALLHAT demonstrated amlodipine equivalence to chlorthalidone for the primary cardiovascular endpoint; CCBs and thiazide-type diuretics are the guideline-preferred first-line agents in Black patients without compelling indications for RAAS inhibition
D) Verapamil 120 mg twice daily — non-DHP CCBs are preferred in Black patients because their cardiac rate-slowing effect reduces pulse pressure, which is the dominant hemodynamic driver of hypertension in this demographic
E) Spironolactone 25 mg daily — mineralocorticoid receptor antagonism is the most physiologically targeted agent in Black patients because their low-renin hypertension is invariably caused by autonomous aldosterone excess
ANSWER: C
Rationale:
Black patients with hypertension typically have a low-renin, volume-expanded hemodynamic profile that makes them less responsive to RAAS inhibitors as monotherapy — confirmed in ALLHAT, where lisinopril was inferior to chlorthalidone for stroke prevention in Black patients. Dihydropyridine CCBs act through a renin-independent mechanism (vascular L-type calcium channel blockade) and are highly effective across all demographic groups. ALLHAT demonstrated amlodipine equivalence to chlorthalidone for the primary composite cardiovascular endpoint across racial groups. Current ACC/AHA guidelines specifically recommend CCBs and thiazide-type diuretics as preferred initial agents in Black patients without compelling indications for other classes. Amlodipine 5 mg is an appropriate and evidence-supported first choice, with chlorthalidone 12.5 mg as an equivalent alternative.
Option A: Option A is incorrect because RAAS inhibitors as monotherapy are generally less effective in Black patients — ALLHAT confirmed lisinopril's inferiority for stroke in this group.
Option B: Option B is incorrect because beta-blockers are most effective in high-renin states; low-renin hypertension in Black patients does not respond well to cardiac output reduction alone, and beta-blockers are not guideline-preferred first-line agents in this demographic.
Option D: Option D is incorrect because verapamil is not preferred over DHP CCBs in Black patients; it carries additional risks of constipation, drug interactions, and cardiac conduction effects without additional antihypertensive benefit.
Option E: Option E is incorrect because while low-renin hypertension can respond to MRAs, spironolactone is a fourth-line agent in resistant hypertension (PATHWAY-2); low-renin essential hypertension in Black patients is not invariably caused by autonomous aldosterone excess, and most patients do not have diagnosable primary aldosteronism.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.